Central Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Central Pharmaceuticals has been growing earnings at an average annual rate of 14%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 36.9% per year.
Key information
14.0%
Earnings growth rate
14.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | -36.9% |
| Return on equity | n/a |
| Net Margin | -50.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Central Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 90 | -46 | 19 | 0 |
| 30 Sep 23 | 54 | -41 | 18 | 0 |
| 30 Jun 23 | 29 | -44 | 19 | 0 |
| 30 Sep 22 | 25 | -68 | 13 | 0 |
| 30 Jun 22 | 26 | -68 | 16 | 0 |
| 30 Jun 21 | 148 | -8 | 22 | 0 |
| 30 Jun 20 | 140 | -1,107 | 611 | 0 |
| 31 Mar 20 | 173 | -545 | 325 | 0 |
| 31 Dec 19 | 206 | 17 | 39 | 0 |
| 30 Sep 19 | 231 | 28 | 40 | 0 |
| 30 Jun 19 | 307 | 57 | 45 | 0 |
| 31 Mar 19 | 355 | 83 | 42 | 0 |
| 30 Sep 18 | 371 | 81 | 54 | 0 |
| 30 Jun 18 | 320 | 61 | 54 | 0 |
| 31 Mar 18 | 272 | 29 | 56 | 0 |
| 30 Sep 17 | 473 | 112 | 62 | 0 |
| 30 Jun 17 | 456 | 109 | 60 | 0 |
| 31 Mar 17 | 485 | 133 | 62 | 0 |
| 31 Dec 16 | 440 | 116 | 62 | 0 |
| 30 Sep 16 | 348 | 81 | 59 | 0 |
| 30 Jun 16 | 417 | 98 | 68 | 0 |
| 31 Mar 16 | 477 | 100 | 85 | 0 |
| 31 Dec 15 | 553 | 122 | 89 | 0 |
| 30 Sep 15 | 624 | 135 | 93 | 0 |
| 30 Jun 15 | 661 | 143 | 94 | 0 |
| 31 Mar 15 | 676 | 161 | 75 | 0 |
| 31 Dec 14 | 715 | 170 | 78 | 0 |
| 30 Sep 14 | 685 | 162 | 76 | 0 |
| 30 Jun 14 | 654 | 152 | 75 | 0 |
| 31 Mar 14 | 612 | 151 | 83 | 0 |
| 31 Dec 13 | 526 | 118 | 76 | 0 |
| 30 Sep 13 | 452 | 91 | 66 | 0 |
| 30 Jun 13 | 424 | 78 | 59 | 0 |
Quality Earnings: CENTRALPHL is currently unprofitable.
Growing Profit Margin: CENTRALPHL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CENTRALPHL is unprofitable, but has reduced losses over the past 5 years at a rate of 14% per year.
Accelerating Growth: Unable to compare CENTRALPHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CENTRALPHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.6%).
Return on Equity
High ROE: CENTRALPHL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.